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| INTRODUCTION
Pulmonary hypertension (PH) is defined as an increase of ≥25 mm Hg in mean pulmonary arterial pressure and a pulmonary capillary wedge pressure ≤15 mm Hg in precapillary PH or >15 mm Hg in postcapillary PH. As a rare and severe disease characterized by an increase in pulmonary vascular resistance, PH shows an increase in the afterload of the right ventricle and then right ventricular failure. Pulmonary hypertension is a major global health issue; it affects approximately 1% of the total population and increases up to 10% among individuals aged >65 years. 1 Despite impressive advancements in elucidation of the pathobiology of PH and the introduction of targeted medical therapies, PH remains a life-threatening disease with a poor prognosis, [2] [3] [4] with estimated survival rates at 1 year, 2 years and 3 years of 95.6%, 87.3% and 77.0%, respectively, in Europe and North America. 5 Thus, it is important to identify novel prognostic therapeutic targets and precise prognostic markers for this type of lung disease. Based on the aforementioned findings, right heart catheterization is the gold standard for diagnosis of PH 6 ; however, it is an invasive technique and provides subjective measures. A noninvasive and objective biomarker for precise diagnosis, treatment efficacy and good prognosis is needed. To date, the assessment of prognosis in PH has been primarily based on clinical symptoms and hemodynamic parameters as follows. Analysis of BNP and NT-proBNP has been performed to evaluate pulmonary arterial hypertension (PAH). 7 Cardiac troponin T (cTnT) can indicate ongoing myocardial damage, as it is a useful biomarker in left heart failure. Interestingly, Filusch and his team found that the novel biomarker highsensitivity Tn T (hs-TnT) was associated with death because of systolic right ventricular dysfunction and an impaired 6-minute walking distance (6MWD). 8 The cTnI level is more sensitive than cTnT for evaluation of cardiovascular risk factors of coronary artery disease in clinical settings. However, no meta-analysis to determine the association between serum cTn and mortality in PH has been performed, and the utility of cTnI or cTnT as a prognostic biomarker in PH is unclear. Therefore, we aimed to test these hypotheses and determine whether cTn positivity was associated with an increased risk of mortality in patients with PH and whether cTnI or cTnT would be a better prognostic biomarker.
| DATE SOURCE
Eligible studies were identified by searching the PubMed and EMBASE databases from inception to October 25, 2017. The Medical Subject Heading (MeSH) terms and free keywords used to identify articles were as follows: (1) 'pulmonary hypertension', 'pulmonary arterial hypertension'; (2) 'cardiac troponin', 'troponin', 'troponin T', 'troponin I'; (3) 'outcome', 'major end events', 'clinical end point', 'death', 'mortality', 'prognosis'. The published language was not limited. Two independent investigators (XXQ and XSL) examined titles and abstracts of all search results. After one investigator regarded a study as potentially eligible, we read the full article and resolved disagreements by discussion.
| STUDY SELECTION
The inclusion criteria were as follows: (1) a retrospective or prospective cohort study; (2) a diagnosis of PH based on World Health Organization (WHO) Evian/Venice classification; (3) determination of serum levels of cTnT or cTnI; (4) an evaluation of the association between cTn and the mortality of PH patients; and (5) the presence of sufficient data to calculate the multivariate-adjusted hazard ratio (HR) and the corresponding 95% confidence intervals (CIs). Studies were excluded based on the following criteria: (1) a review, abstract or letter; (2) use of animals; and (3) duplicate report. If the data were duplicated or the same population was used in more than one study, we chose the most recent or complete study.
This finding was independent of the follow-up length of the studies (≤3 years: HR = 2.36, 95%CI = 1.65-3.38; >3 years: HR = 4.55, 95%CI = 2.80-7.39). Conclusions: Although different studies detected the expression cTnT or cTnI by various methods, the mortality in the cTn-positive group was higher than that in the cTn-negative group. Serum cTn elevation emerged as an independent predictor of increased risk of mortality in PH patients.
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| DATA EXTRACTION
According to the aforementioned selection criteria, data extraction was performed by one investigator (XSL) and verified by a second investigator (XXQ). The following information was extracted from the eligible studies: the name of the first author, publication year, study period, country, study type, sample number, sex of patients, median follow-up period, mean age or age range of patients, study outcome, PH disease type, cause of death and cTn data (Tables 1-3). Table 2 was generated based on the 2013 5th World Symposium. In addition, HR and 95% CIs were evaluated. Two authors (YJ and ZY) summarized the extracted data. Any disagreements were resolved by discussion.
| QUALIT Y ASSESSMENT AND ENDPOINTS
The Newcastle-Ottawa Scale (NOS) 9 was used for methodological quality assessment of a cohort study and has three parameters: selection, comparability and outcome. The total NOS score was 9. Low quality was defined as a NOS score <7.0. Otherwise, the study was defined as high quality. The primary endpoint was the incidence of mortality. For complementary analyses, we considered the relationship between Tn elevation and mortality, stratifying for the following: (1) value of TnT vs value of TnI in patients with PH; (2) European populations vs American populations; (3) studies with a follow-up ≤3 years vs those with a follow-up >3 years.
| STATISTICAL ANALYSES
We calculated the pooled hazard ratio (HR) and 95% confidence interval (CI) and used the Q-test and the I 2 test to assess heterogeneity among the studies. 10 We also calculated the P values of the Q-test, which represent heterogeneity; values of P ≤ 0.10 or I 2 ≥ 50% indicated heterogeneity among studies, and a random effect model was used. 11 Otherwise, the fixed effects model was applied. 12 Analyses based on Tn, Tn type, region and follow-up times were performed. Additionally, a sensitivity analysis was performed by sequentially omitting one study for each factor analysed to evaluate the stability of the results. 13 Finally, Begg's rank correlation test and Egger's linear regression test were conducted to assess the extent of potential publication bias. 7 | RESULTS
| Literature search and study characteristics
Using the predefined search strategy, we retrieved 378 articles (102 from PubMed and 276 from EMBASE). Among these articles, after removal of duplicates, 281 studies were identified from the database search. Then, 273 studies were excluded after screening the titles and abstracts and reviewing the full text. Finally, eight articles [15] [16] [17] [18] [19] [20] [21] [22] involving 739 participants were included in our analysis. The detailed study selection process is presented in Figure 1A .
The characteristics of the eight eligible studies, which had subjects ranging in age from 26 to 75.8 years, are shown in Table 1 . Five studies were performed in Europe and included 385 participants, and 3 studies were performed in America and included 354 participants. The eight cohort studies consisted of six prospective studies, one retrospective study, and one special prospective and retrospective study. There were many types of PH disease, and the study outcomes were mortality and hospitalization. A total of 192 patients died (mortality 26.0%) among the 739 participants. The NOS scores of the eight cohort studies are summarized in Table 1 , and the percentage chart ( Figure 1B) shows the NOS judgements for each numbered item across all included studies. Eight articles were high-quality studies (scores >7.0). PH disease composition and cause of death are shown in Table 2 .
The data on cTn are shown in Table 3 . Overall mortality was reported in all studies, cTnT in five studies, and cTnI in two studies, and one study reported data on both cTnT and cTnI. Positive cTn was detected by different assays with inconsistent cut-off values, and the high-sensitivity assay had a cut-off range from 1.2 ng/L to 14 ng/L in five studies. Six of eight studies used a pooled HR with 95%CI via multivariate Cox proportional hazards analysis. Positive cTn in these patients ranged from 14.3% to 94.5%. Furthermore, excluding incomplete data, the data showed that 55.8% (351/629) of the patients had high cTn, and 48.8% (39/80) of patients with elevated cTn died compared with 18.6% (45/242) of patients with normal cTn levels. 
| Quantitative analysis

| Sensitivity analysis
A sensitivity analysis used to evaluate the robustness of our analysis by recalculating the pooled results from the primary analyses after excluding one study per iteration. None of the studies when excluded altered the overall combined results ( Figure 6 ).
| Publication bias
No evidence of publication bias was found based on the Begg's rank correlation test (P>|z| = 0.251) or Egger's linear regression test (P > |z| = 0.231) (Figure 7 ).
| DISCUSSION
An enhanced understanding of the incidence, morbidity and mortality of PH could help improve the prevention and treatment of this disease in the future. To date, improving survival rates has been a challenge because PH is a rare subtype of lung disease with a high mortality and low survival rate.
To overcome this problem, we performed a comprehensive meta-analysis of available studies to examine the value of cTn elevation to predict mortality in PH for the first time. The primary results of this study showed that serum cTn was associated with an increased risk of PH. In our present meta-analysis, cTn was positively associated with an increased risk of mortality (HR = 3.05, 95%CI = 2.16-4.32), indicating that high cTn indeed predicts poor survival in PH. Low heterogeneity was found; therefore, the fixed effects model was applied when I 2 = 24.9% and P = 0.223. The quality of eight cohort studies was good with high NOS scores, and the results indicated no statistically significant heterogeneity by subgroup analysis, excellent sensitivity analysis and no publication bias. Although different studies detected the expression cTnT or cTnI by inconsistent methods, the mortality in the cTn positive group was high compared with that in the cTn negative group, and cTnI elevation could be a better predictor of mortality than cTnT. In addition, American populations had increased mortality compared to European populations. As the follow-up times increased, increased mortality was observed.
Different classifications of PH are associated with the development of PH. 23 In this meta-analysis, most of the 739 patients were diagnosed with PAH, PH due to left heart disease, PH due to lung disease and chronic thromboembolic pulmonary hypertension. Among these classifications, PAH, especially idiopathic PAH, has an important position. However, if the population resided at a higher altitude, a trend of higher risk of PH was observed. Therefore, different regions have different incidence and mortality rates. 24 The average altitude in America is higher than that in Europe, and American populations had increased mortality compared to European populations. These results are highly consistent with our findings, and we believe that mortality closely related to the WHO functional class. However, Strange's team believed that the epidemiology and survival of patients with idiopathic PAH in Australia and New Zealand were similar to contemporary registries reported in Europe and North America. In most previous studies, cTn levels have been shown to be related to cardiovascular risk factors of coronary artery disease. 25 Recently, several studies found that an increase in cTn levels was associated with adverse clinical outcomes in patients with PH [15] [16] [17] [18] [19] [20] [21] [22] ; differences in sample size, followup, type of Tn and cut0-off values among various studies may explain these discrepancies (Table 3) . Hs-TnT levels are detected by new assays, which measure concentrations at the 99th percentile in a reference population with a 10-fold lower detection range than traditional assays and are available for clinical use and research. 26 The Torbicki group first reported the potential prognostic role of detectable cTnT in PAH. Although the prevalence of detectable cTnT was only 14%, elevated levels were associated with a poor prognosis. 15 In our findings, the prognostic value of Tn was consistent among the studies, regardless of the specific assay and the relative cut-off point. The results were consistent for both cTnI and cTnT. Thus, regardless of the assay used, Tn levels can be used to stratify patients with PH. The role of cTn elevation as an independent predictor of increased risk of mortality in PH patients remains controversial. In a preclinical study, cTnI levels were not markers of mortality and disease severity in infants with PH. 27 However, our work supported the opposite finding in adults with an age range from 26 to 75.8 years, and a cTnI elevation of 1.1 times successfully predicted all-cause mortality compared with cTnT. The results of Eggers's team are highly consistent with our findings. 17 Furthermore, the underlying mechanism for cTn elevation during PH is unclear. Eggers et al reported that Tn levels were associated with a low cardiac index, high pulmonary artery pressure and high pulmonary vascular resistance. 17 Another study also showed that this increase could be related to pulmonary vascular resistance, increased intramural right ventricular tension and eventually decreased cardiac output, which can lead to right ventricular myocardial ischemia and necrosis. 19 Future studies are needed to determine how to manage these high-risk patients and how to improve their outcome. Regardless of its strengths, this meta-analysis also has certain limitations. First, some published studies not available in the online databases were missed. In addition, studies with negative or nonsignificant results may have been rejected or missed by journals. Second, one special study with cTnT and cTnI was included, and we treated it as two articles, so bias cannot be eliminated. Third, the adjustment factors for multivariate analysis were significantly different among the studies. Two of eight cohort studies pooled the HR and 95% CI by univariate Cox proportional hazards analysis. Fourth, we could not control for the differences in cTn measurements in the eight studies, which had inconsistent cut-off values ranging from 1.2 ng/L to 10 000 ng/L. In addition, we limited our analysis to mortality. This is principally because of the absence of sufficient data from studies on the relationship between Tn elevation and other adverse events (eg, cardiac death, myocardial infarction and heart failure).
| CONCLUSIONS
In summary, this meta-analysis indicated that although different studies detected the expression cTnT or cTnI by inconsistent methods, the mortality in the cTn-positive group was higher than that of the cTn-negative group. Serum cTn elevation emerged as an independent predictor of increased risk of mortality in PH patients. Higher quality and more comprehensive analyses are still needed in the future.
